BioSpace News Archive

Sun Pharmaceutical Industries, Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited, released results of a survey revealing defeatist attitudes about treatment among people with mild-to-moderate acne, despite feelings of self-consciousness.

Verana Health® announce a partnership focused on providing the life sciences community with deeper and broader data to optimize and expedite clinical trials.

Seres Therapeutics, Inc., a leading microbiome therapeutics company, reported financial results for the third quarter ended September 30, 2023, including VOWST net sales of $7.6 million.

Trevi Therapeutics, Inc. announced the initiation of its Phase 2a RIVER clinical trial evaluating Haduvio in RCC patients.

Tonix Pharmaceuticals Holding Corp. today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), will conduct a Phase 1 clinical trial with TNX-1800 (recombinant horsepox virus, live vaccine),1 Tonix Pharmaceuticals’ vaccine candidate to protect against COVID-19.

Bionano Genomics, Inc., announced that optical genome mapping was included for the first time in Thompson and Thompson Genetics and Genomics in Medicine, 9th edition, a textbook regularly used for medical students, genetic counseling students, students in laboratory medicine, and more advanced trainees pursuing ABMGG residency and laboratory fellowships in clinical biochemical genetics, laboratory genetics and genomics, and clinical molecular genetics.

Outlook Therapeutics, Inc. announced that it has completed the requested Type A Meetings with the U.S. Food and Drug Administration to discuss the Complete Response Letter dated August 29, 2023 regarding the Biologics License Application for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.

Ractigen Therapeutics presented recent preclinical results at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Vaxart, Inc. announced it has dosed the first subject in its Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate focused on lactating mothers.

Regulus Therapeutics Inc. today announced the dosing of the first patient in the third cohort of the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD.